Rebounding growth could make shares of this leading drugmaker a big winner.Bristol Myers Squibb (BMY 0.46%) has struggled to manage the loss of exclusivity now that some of its top-selling drugs are facing competition from generics. Disappointing results from the pharmaceutical giant have pressured the stock in recent years; it's currently down about 34% from its record high in 2022.The backdrop is concerning. But the good news is that the company's latest update signaled what could be the start of a long-a ...

No stock is perfect, but quality businesses can stand the test of time in your portfolio.While a full-fledged, prolonged stock market correction could impact shares across a range of industries, investors with capital on hand can find that these periods present fortuitous opportunities to put cash to work. If you have the risk appetite to invest right now, there are plenty of tried-and-true businesses that have stood the test of time and can do so in a long-term investor's portfolio.Large-cap stocks, which ...

Bristol Myers Squibb (BMY) ended the recent trading session at $49.95, demonstrating a +0.46% swing from the preceding day's closing price. This move lagged the S&P 500's daily gain of 1.01%. Elsewhere, the Dow gained 0.55%, while the tech-heavy Nasdaq added 1.13%.Shares of the biopharmaceutical company have appreciated by 3.22% over the course of the past month, underperforming the Medical sector's gain of 4.91% and outperforming the S&P 500's gain of 2.5%.The upcoming earnings release of Bristol Myers Squ ...

Key TakeawaysSeveral pharmaceutical stocks moved higher Wednesday, bucking downward pressure on the broader markets.An array of clinical trial results and regulatory decisions helped boost shares of Gilead Sciences, Bristol-Myers Squibb, and Vertex Pharmaceuticals.The pharma industry has underperformed in 2024 despite several companies making headlines with blockbuster weight-loss treatments. Shares of several drugmakers and biotechnology firms moved higher on Wednesday, notching some of the day's top perfo ...

Unlock steady income and growth potential with these high-yield, low-risk dividend powerhouses.High-yield dividend stocks can be enticing, with several academic studies showing that stocks yielding above 3% tend to outperform most other asset classes when held for 20 years or longer. However, dividend yield isn't the most important metric to consider when evaluating stocks with cash or stock distributions.A recent report by Hartford Funds reveals a crucial insight: Dividend stocks with payout ratios below 7 ...

These underappreciated dividend payers offer yields above 4% at recent prices.The past year has been terrific for most stocks. The S&P 500 index rose 27.5% during the 12 months ended Aug. 26.It's always nice to see the value of your portfolio rise during a bull market, but it also makes it hard to find stocks to buy at reasonable valuations.Investors seeking reliable dividend stocks that still look like bargains will be glad to know that not all of the S&P 500's components have had a great year. Pfizer (PFE ...

Bristol Myers (BMY) announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for the immunotherapy drug, Opdivo (nivolumab), in combination with Yervoy (ipilimumab).The sBLA seeks approval of Opdivo plus Yervoy as a potential first-line treatment option for adult patients with unresectable hepatocellular carcinoma (HCC). A final decision from the regulatory body in the United States is expected on Apr 21, 2025.Bristol Myers’ application is based on results from the late-stag ...

Bristol Myers Squibb (BMY) announced that the European Medicines Agency (“EMA”) has validated its type II variation application to expand the indication for CD19-directed chimeric antigen receptor (CAR) T cell therapy Breyanzi (lisocabtagene maraleucel; liso-cel).The application seeks to expand Breyanzi’s label to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy.Validation of the application confirms th ...

With yields above 4%, these stocks could do a lot to boost your passive income streamThe S&P 500 index is up by about 16% so far this year. Many of the index's dividend payers have raised their payouts, but not nearly as much as their stock prices have risen. As a result, the average dividend-paying stock in the benchmark index offers a paltry 1.3% yield at recent prices.Luckily, there are still a handful of top dividend payers trading for low enough prices to offer high yields. Here's why they could be gre ...

The drugmaker will go through key changes by the end of the decade.Bristol Myers Squibb (BMY 0.51%) has had a rough past five years. Its shares are barely in the green, its financial results have been unimpressive, and it has faced important patent cliffs. Most notably, its cancer drug Revlimid, its top-selling product at one point, is now out of patent exclusivity.Despite that poor showing in recent years, things might be very different for BMS in the next half-decade, but only if it can better handle the ...